horstem
equicord s.l. - equine navlestreng mesenchymal stem cells - andre legemidler for forstyrrelser i muskel-skjelettsystemet - hester - reduksjon av halthet forbundet med mild til moderat degenerative joint sykdom (artrose) i hester.
beovu
novartis europharm limited - brolucizumab - wet macular degeneration - Øyemidler - beovu er angitt i voksne for behandling av neovascular (våt) aldersrelatert makuladegenerasjon (amd).
olimel n12
baxter medical ab - alanin / arginin / aspartinsyre / glutaminsyre / glysin / histidin / isoleucin / leucin / lysinacetat / metionin / fenylalanin / prolin / serin / treonin / tryptofan / tyrosin / valin / glukosemonohydrat / soyaolje, renset / olivenolje, renset - infusjonsvæske, emulsjon
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - Øyemidler - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - Øyemidler - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - Øyemidler - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
tafinlar
novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuvant behandling av melanomadabrafenib i kombinasjon med trametinib er indikert for adjuvant behandling av voksne pasienter med stadium iii melanom med en braf v600 mutasjon, følgende komplett reseksjon. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
curacit 10 mg/ ml
takeda as - suksametoniumklorid - injeksjonsvæske, oppløsning - 10 mg/ ml